Navigating the Art of Healthcare Finance Management
In a significant move towards improving healthcare and reducing costs, more than 2.04 trillion rubles will be allocated to the national projects "Long and Active Life" and "New Technologies for Health Preservation" from 2025 to 2030. This investment is part of the Russian government's active approach to developing pharmaceutical innovations.
One such innovation is the use of empagliflozin-based drugs in patients with breast cancer, which has shown significant cost savings. The mechanism of savings in pharmaceuticals is based on effective drugs reducing healthcare costs by decreasing disability levels and medical service spending.
The use of innovative drugs has also increased life expectancy by approximately 1.7 years in countries that widely use them over the past decade. In 2025, the number of vital and essential drugs in the Ministry of Health's list increased by 18, including modern drugs for the treatment of oncological diseases, diabetes, and cardiovascular diseases.
The market for semaglutide-based drugs, used for treating diabetes and obesity, has seen a surge in Russia. In 2024, commercial sales reached a record high of 8.8 billion rubles, with government purchases adding another 1.7 billion rubles. The use of Russian analogues of semaglutide and tirzepatide may potentially reduce Russia's budget expenses by 20 billion rubles per year in the medium term.
The centralization of drug purchases, implemented in 44 regions of Russia, is another cost-saving measure. Regions such as Primorye, Bashkortostan, and Krasnoyarsk Krai have reported savings of 20%, 10%, and 7% of their budgets respectively.
Progress in cancer treatment is linked to the emergence of targeted therapy and immunotherapy, which act on specific molecular structures of tumor cells, making treatment more effective and less toxic. Innovative drugs, such as those containing the active substance acalabrutinib, have shown impressive results in reducing the risk of leukemia progression or death.
The use of these innovative drugs prevented around 5,000 deaths from colorectal cancer, 34,000 from lung cancer, and over 11,000 from breast cancer in 2024 alone. The global economic impact of semaglutide is estimated to be a staggering $429 billion annually from 2020 to 2060, with sales estimated at $47 billion per year.
The introduction of biosimilars has also played a crucial role in reducing treatment costs, leading to cost reductions of up to 81% in some countries. The expected cumulative savings in the U.S. due to competition between original biological drugs and biosimilars over five years (2019-2024) is around $100 billion.
In conclusion, pharmaceutical innovations are an effective tool for optimizing the healthcare system's economy, ensuring significant savings of budget funds in the long term due to a decrease in the number of hospitalizations, a reduction in the number of disabled people, and an increase in the working ability of citizens. The Russian government's investment in these projects is a step towards a healthier and more cost-effective future for the country.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
